REFERENCES

• Abitorabi MA, Mackay CR, Jerome EH, Osorio O, Butcher EC, Erle DJ. Differential expression of homing molecules on recirculating lymphocytes from sheep gut, peripheral and lung lymph. J Immunol 1996;156:3111-7.
• Abraham E. Shah S. Intranasal immunisation with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. J Immunol 1992;149:3719-26.
• Aggerbeck H. Gizurarson S. Wantzin J. Heron I. Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 1997;15:307-16.
• Alho OP, Koivu M, Sorri M, Rantakallio P. Risk factors for recurrent acute otitis media and respiratory infections in infancy. Int J Pediatr Otolaryngol 1990;19:151-61.
• Anderson PW, Pichichero ME, Stein EC, Porcelli S, Betts RF, Connuck DM, Korones D, Insel RA, Zahradnik JM, Eby R. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphteria protein CRP₁₉₇. J Immunol 1989;142:2464-8.
• Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatrics 1996;128:649-53.
• Aniansson G, Alm B, Andersson B, Larsson P, Nylen O, Peterson H, Rigner P, Svanborg M, Svanborg C. Nasopharyngeal colonization during the first year of life. J Infect Dis 1992;165:S38-42.
• Anttila M, Eskola J, Åhman H, Käyhty H. Avidity of Streptococcus pneumoniae type 6B and 23F polysaccharides of infants primed with pneumococcal conjugates and boostered with polysaccharide or conjugate vaccines. J Infect Dis 1998;177:1614-21.
• Arola M, Ziegler T, Ruuskanen O, Mertsola J, Näntö-Salonen K, Halonen P. Rhinovirus in acute otitis media. J Pediatr 1988;113:693-5.
• Arola M. Ruuskanen O. Ziegler T. Mertsola J. Nanto-Salonen K. Putto-Laurila A. Viljanen MK. Halonen P. Clinical role of respiratory virus infection in acute otitis media. Pediatrics 1990;86:848-55.
• Austrian R, Howie VM, Ploussard JH. The bacteriology of pneumococcal otitis media. Johns Hopkins Med J 1977;141:104-10.
• Austrian R, Douglas RM, Geldmacher KM, Donnelly J, Mendelman PM. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians. 1976;89:184-9.
• Austrian R, Boettger C, Dole M, Fairly L, Freid M. Streptococcus pneumoniae type 16A, a hitherto undescribed pneumococcal type. J Clin Microbiol 1985;22:127-8.
• Avery OT and Goebel WF. Chemoimmunological studies on conjugated carbohydrate proteins: II. Immunological specificity of synthetic sugar-protein antigens. J. Exp. Med. 1929;50:533-50.
• Baker PJ, Amsbaugh DF, Stashak PW, Caldes G, Prescott B. Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells. Rev Infect Dis 1981;3:332-341-8.
• Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ (ed.): Manual of clinical microbiology, 5th ed. Washington DC: American Society for Microbiology, 1991.
• Barington T. Juul L. Gyhrs A. Heilmann C. Heavy-chain isotype patterns of human antibody-secreting cells induced by Haemophilus influenzae type b conjugate vaccines in relation to age and preimmunity. Infect Immun 1994;62:3066-74.
• Barrett DJ. Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 1986;63:127-34.
• Barrett DJ, Sleasman JW, Schatz DA, Steinitz M. Human anti-pneumococcal polysaccharide antibodies are secreted by the CD5-B cell lineage. Cell Immunol 1992;143:66-70.
• Bernstein JM. Scheeren R. Schoenfeld E. Albini B. The distribution of immunocompetent cells in the compartments of the palatine tonsils in bacterial and viral infections of the upper respiratory tract. Act Oto Laryngol 1988;454:S153-62.
• Black SB. Shinefield HR. Fireman B. Hiatt R. Safety, immunogenicity, and efficacy in infancy of oligosaccharideconjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. J Inf Dis1992;165:S139-43.
• Black S, Shinefield H, Ray P, Lewis E, Fireman B, Austrian R, Siber G, Hackell J, Kohberger R, Chang I. Efficacy of heptavalent pneumococcal vaccine in 37,000 infants and children: Results of the Northen California Kaiser Permanete efficacy study. Pneumococcal Vaccines for the World 1998 Conference,Washington DC.
• Black SB. Efficacy of heptavalent conjugate pneumococcal vaccine in 7,000 infants and children: Results of the Northen California Kaiser Permanete efficacy study. Pediatric Academic Societes 1999 Annual Meeting, San Francisco.
• Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992;11:S7-11.
• Booy R. Hodgson S. Carpenter L. Mayon-White RT. Slack MP. Macfarlane JA. Haworth EA. Kiddle M. Shribman S. Roberts JS. et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994;344:362-6.
• Boulnois GJ. Pneumococcal proteins and the pathogenesis of disease caused by Streptococcus pneumoniae. J Gen Microbiol 1992;138:249-59.
• Bouvet JP, Fischetti VA. Diversity of antibody-mediated immunity at the mucosal barrier. Infect Immun 1999;67:2687-91.
• Brandtzaeg P. Human secretory immunoglobulins II. Salivary secretions in individuals with selectively excessive or defective synthesis of serum immunoglobulins. Clin Exp Immunol 1971;8:69-85.
• Brandtzaeg P, Baekkevold ES, Farstad IN, Jahnsen FL, Johansen FE, Nielsen EM, Yamanaka T. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol Today 1999;20:141-51.
• Brandtzaeg P. Nilssen DE. Rognum TO. Thrane PS. Ontogeny of the mucosal immune system and IgA deficiency. Gastroenterol Clin North Am 1991;20:397-439.
• Brandtzaeg P. Kett K. Rognum TO. Söderström R. Bjorkander J. Söderström T. Petrusson B. Hanson LA. Distribution of mucosal IgA and IgG subclass-producing immunocytes and alterations in various disorders. Monog Aller 1986;20:179-94.
• Brandtzaeg P. Bjerke K. Kett K. Kvale D. Rognum TO. Scott H. Sollid LM. Valnes K. Production and secretion of immunoglobulins in the gastrointestinal tract. Ann Allerg 1987;59:21-39.
• Breukels MA. Rijkers GT. Voorhorst-Ogink MM. Zegers BJ. Sanders EA. Pneumococcal conjugate vaccine primes for polysaccharide inducible IgG2 antibody response in children with recurrent otitis media acuta. J Infect Dis 1999;179:1152-6.
• Briles DE, Nahm M, Schroer K, Davie J, Baker P, Kearney J, Barletta R. Antiphosphocholine antibodies found in normal mouse serum are protective against intraveneous infection with type 3 Streptococcus pneumoniae. J Exp Med 1981;153:694-705.
• Briles DE. Yother J. McDaniel LS. Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Inf Dis 1988;10:S372-4.
• Briles DE, Forman C, Horowitz JC, Volanakis JE, Benjamin jr WH, McDaniel LS, Eldridge J, Brooks J. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun 1989;57:1457-64.
• Brown EJ, Hosea SW, Frank MM. The role of antibody and complement is the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis 1983;5:S797-805.
• Bruyn GA, Zegers BJ, van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis 1992;14:251-62.
• Butcher EC and Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-6.
• Butler JE, Spradling JE, Rowat J, Ekstrand J,Challacombe SJ. Humoral immunity in root caries in an elderly population. II. Collection, processing, preservation of antibody activity and influence of diurnal and monthly variation collection procedures. Oral Microb Immunol 1990;5:113-20.
• Bylander A, Tjenström O. Changes in Eustachian tube function with age in children with normal ears. Acta Otolaryngol 1983;96:467-77.
• Bylander A. Comparison of Eustachian tube function in children and adults with normal ears. Ann Otol Rhinol Laryngol 1980;89(suppl 68):20-4.
• Carlsen BD. Kawana M. Kawana C. Tomasz A. Giebink GS. Role of the bacterial cell wall in middle ear inflammation caused by Streptococcus pneumoniae. Infect Immun 1992;60:2850-4.
• Chonmaitree T, Howie VM, Truant AL. Presence of respiratory viruses in middle ear fluids and nasal wash specimens from children with acute otitis media. Pediatrics 1986;77:698-702.
• Crain MJ. Waltman WD 2d. Turner JS. Yother J. Talkington DF. McDaniel LS. Gray BM. Briles DE. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun 1990;58:3293-9.
• Crook J. Tharpe JA. Johnson SE. Williams DB. Stinson AR. Facklam RR. Ades EW. Carlone GM. Sampson JS. Immunoreactivity of five monoclonal antibodies against the 37-kilodalton common cell wall protein (PsaA) of Streptococcus pneumoniae. Clin Diagn Lab Immunol 1998;5:205-10.
• Cundell DR. Gerard NP. Gerard C. Idanpään-Heikkilä I. Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995;377:435-8.
• Czerkinsky CC, Nilsson L-Å, Nygren H, Ouchterlony Ö, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody secreting cells. J Immunol Methods 1983;65:109-21.
• Dagan R, Melamed R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigen. Pediatric Infect Dis J 1997;16:1053-9.
• Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunisation with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphteria toxoid. Pediatric Infect Dis J 1996;16:1060-4.
• Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O, Mendelman PM, Bohidar N and Yagupsky P. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. Infec. Dis 1996;174:1271-8.
• Darville T. Jacobs RF. Lucas RA. Caldwell B. Detection of Haemophilus influenzae type b antigen in cerebrospinal fluid after immunisation. Ped Inf Dis J 1992:11:243-4.
• Delacroix DL, Dive C, Rambaud JC, Vaerman JP. IgA subclasses in various secretions and serum. Immunology 1982;47:383-5.
• Douce G. Turcotte C. Cropley I. Roberts M. Pizza M. Domenghini M. Rappuoli R. Dougan G. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Nat Acad Sci USA 1995;92:1644-8.
• Douce G. Fontana M. Pizza M. Rappuoli R. Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 1997;65:2821-8.
• Eby R. Pneumococcal conjugate vaccines. Vaccine Design: The subunit and adjuvant approach. Plenum Press, New York 1995, Chapt 31, 695-718.
• Eskola J. Käyhty H. Takala AK. Peltola H. Rönnberg PR. Kela E. Pekkanen E. McVerry PH. Mäkelä PH. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. New Engl J Med 1990;323:1381-7.
• Faden H, Stanievich J, Brodsky L, Bernstein J, Ogra PL. Changes in nasopharyngeal flora during otitis media in childhood. Pediatr Infect Dis J 1990;9:623-6.
• Fattom A, Lue C, Szu SC, Mestecky J, Schiffman G, Bryla D, Vann WF, Watson D, Kimzey LM, Robbins JB et al. Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphteria toxoid. Infect Immun 1990;58:2309-12.
• Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin S, Orenstein WA (eds): Vaccines, W.B. Sanders Company, Philadelphia, 1999, pp553-607.
• Fehr T. Naim HY. Bachmann MF. Ochsenbein AF. Spielhofer P. Bucher E. Hengartner H. Billeter MA. Zinkernagel RM. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nat Med 1998;4:945-8.
• Feldman C, Mitchell TJ, Andrew PW, Boulnois GJ, Read RC, Todd HC, Cole PJ, Wilson R. The effect of Streptococcus pneumoniae on human respiratory epithelium in vitro. Microb Pathog 1990;9:275-84.
• Ferrante A, Rowan-Kelly B, Paton JC. Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin. Infect Immun 1984;46:585-9.
• Flanagan MP. Michael JG. Oral immunisation with a Streptococcal pneumoniae polysaccharide conjugate vaccine in enterocoated microparticles induces serum antibodies against type specific polysaccharides. Vaccine 1999;17:72-81.
• Fontana MR. Manetti R. Giannelli V. Magagnoli C. Marchini A. Olivieri R. Domenighini M. Rappuoli R. Pizza M. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect Immun 1995;63:2356-60.
• Garcia P. Garcia JL. Garcia E. Lopez R. Nucleotide sequence and expression of the pneumococcal autolysin gene from its own promoter in Escherichia coli. Gene 1986;43:265-72.
• Giebink GS. The microbiology of otitis media. Pediatr Infect Dis J 1989;8:18-20.
• Gillespie SH. Aspects of pneumococcal infection including bacterial virulence, host response and vaccination. J Med Microbiol 1989;28:237-48.
• Gizurarson S. Georgsson G. Aggerbeck H. Thorarinsdottir H. Heron I. Evaluation of local toxicity after repeated intranasal vaccination of guinea-pigs. Toxicology 1996;107:61-8.
• Goebel WF. Studies on antibacterial immunity induced by artifical antigens. I. Immunity to experimental pneumoccal infection with an antigen containing cellobiuronic acid. J Exp Med 1939;69:353-64.
• Gowans JL, Knight EJ. The route of re-circulation of lymphocytes in the rat. Proc Roy Soc (Ser B) 1964; 159:257-82.
• Granoff DM. Gilsdorf J. Gessert CE. Lowe L. Haemophilus influenzae type b in a day care center: relationship of nasopharyngeal carriage to development of anticapsular antibody. Pediatrics 1980;65(1):65-8.
• Granoff DM and Lucas AH. Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunological memory. Ann NY Acad Sci 1995;745:278-88.
• Gratten M. Gratten H. Poli A. Carrad E. Raymer M. Koki G. Colonisation of Haemophilus influenzae and Streptococcus pneumoniae in the upper respiratory tract of neonates in Papua New Guinea: primary acquisition, duration of carriage, and relationship to carriage in mothers. Biol Neon 1986;50:114-20.
• Gray BM. Dillon HC Jr. Clinical and epidemiologic studies of pneumococcal infection in children. Ped Inf Dis 1986;5:201-7.
• Gray BM. Pneumococcal infections in an era of multiple antibiotic resistance. Adv Ped Inf Dis 1996;11:55-99.
• Gray BM, Converse GM, Huhta N, Johnston RB Jr, Pichichero ME, Schiffman G, Dillon HC Jr. Epidemiological studies of Streptococcus pneumoniae in infants: antibody response to nasopharyngeal carriage of types 3, 19 and 23. J Infect Dis 1981;144:312-8.
• Gray BM, Converse GM, Dillon HC. Epidemiologic Studies of Streptococcus pneumoniae in Infants. Acquisition, carriage, and infection during the First 24 Months of Life. J Infect Dis 1980;142:923-33.
• Greenfield S. Peter G. Howie VM. Ploussard JH. Smith DH. Acquisition of type-specific antibodies to Hemophilus influenzae type b. J Pediatrics 1972;80:204-8.
• Griffioen AW, Rijkers GT, Janssens-Korpela P, Zegers BJM. Pneumococcal polysaccharide complexed with C3d bind to human B lymphocytes via complement receptor type 2. Infect Immun 1991;59:1839.
• Griffioen AW. Toebes EA. Rijkers GT. Claas FH. Datema G. Zegers BJ. The amplifier role of T cells in the human in vitro B cell response to type 4 pneumococcal polysaccharide. Immunol Lett.1992; 32:265-72.
• Griffioen AW. Toebes EA. Zegers BJ. Rijkers GT. Role of CR2 in the human adult and neonatal in vitro antibody response to type 4 pneumococcal polysaccharide. Cell Immunol.1992;143:11-22.
• Griffioen AW, Franklin SW, Zegers BJM, Rijkers GT. Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes. Clin Immunol Immunopathol 1993;69:1-8.
• Grönblad EA. Concentrations of immunoglobulins in human whole saliva: effect of physiological stimulation. Acta Odontol Scand 1981;40:87-95.
• Heikkinen T. Thint M. Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999;340:260-4.
• Heilmann C, Barington T, Sigsgaard T. Subclass of individual IgA human lymphocytes. Investigation of In Vivo pneumococcal polysaccharide-induced and in vitro mitogen-induced blood B cells by monolayer plaque-forming cell assays .Immunol 1988;140:1496-9.
• Heilmann C, Pedersen FK. Quantitation of blood lymphocytes secreting antibodies to pneumococcal polysaccharides after in vivo antigenic stimulation. Scand J Immunol 1986;23:189-94.
• Heilmann C, Henrichsen J, Pedersen FK. Vaccination-induced circulation of human B cells secreting type-specific antibodies against pneumococcal polysaccharides. Scand J Immunol 1987;25:61-7.
• Henderson FW, Giebink GS. Otitis media among children in day care: epidemiology and pathogenesis. Rev Infect Dis 1986;8:533-8.
• Hendley JO, Sande MA, Stewart PM, Qwaltney JM Jr. Spread of Streptococcus pneumoniae in families I. Carriage rates and distribution of types. J Infect Dis 1975;132:55-61.
• Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995;33:2759-62.
• Herva E, Luotonen J, Timonen M, Sibakov M, Karma P, Mäkelä PH. The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of Sreptococcus pneumoniae. Scand J Infect Dis 1980;12:97-100.
• Holmgren J. Lycke N. Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 1993;11:1179-84.
• Holzer TH, Edwards KM, Gewurz H, Mold K. Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differental localization of C3 and stimulation of phagocytosis. J Immunol 1984;133:1424-30.
• Hostetter MK. Serotypic variations among virulent pneumococci in deposition and degradation of covalently boud C3b: Implications for phagosytosis and antibody production. J Infect Dis 1986;153:682-93.
• Howie VM, Ploussard JH, Sloyer J. The "otisis-prone" condition. Am J Dis Child 1975;129:676-8.
• Jakobsen H, Saeland E, Gizurarson S, Schults D, Jonsdottir I. Intranasal immunisation with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect Immun 1999;67:4128-33.
• Johnson MK. Cellular location of pneumolysin. FEMS Microbial Lett 1977;2:243-5.
• Johnson MK. Boese-Marrazzo D. Pierce WA Jr. Effects of pneumolysin on human polymorphonuclear leukocytes and platelets. Infect Immun 1981;34:171-6.
• Johnston RB Jr. The host response to invasion by Streptococcus pneumoniae: protection and the pathogenesis to tissue damage. Rev Infect Dis1981;3:282-8.
• Johnston RB Jr. Pathogenesis of pneumococcal pneumonia. Rev Infect Dis 1991;13:S509-17.
• Kaijser B. Ahlstedt S. Protective capacity of antibodies against Escherichia coli and K antigens. Infect Immun 1977;17:286-9.
• Kanclerski K,Möllby L. Production and purification of Streptococcus pneumonie hemolysin (pneumolysin). J Clin Microbiol 1987;25:222-5.
• Kantele A, Arvilommi H, Jokinen I. Specific immunoglobulin-secreting human cells after peroral immunisation against Salmonella typhi. J Infect Dis 1986;153:126-31.
• Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 1990;8:321-6.
• Kantele A, Papunen R, Virtanen E, Möttönen T, Räsänen L, Ala-Kaila K, Mäkelä PH, Arvilommi H. Antibody-secreting cells in acute urinary tract infection as indicators of local immune response. J Infect Dis 1994;169:1023-8.
• Kantele A, Takanen R, Arvilommi H. Immune response to acute diarrhea seen as circulating antibody secreting cells. J Infect Dis 1988;158:1011-6.
• Kantele A, Kantele J, Honkinen O, Mertsola J, Arvilommi H. Antibody secreting cells in upper urinary tract infection: comparison of the response in children and adults. Adv Exp Med Biol 1995;371B:991-4.
• Kaplan GJ. Fleshman JK. Bender TR. Baum C. Clark PS. Long-term effects of otitis media: a ten-year cohort study of Alaskan Eskimo children. Pediatrics 1973;52:577-85.
• Karjalainen H, Koskela M, Luotonen J, Herva E, and Sipilä P. Antibodies against Streptococcus pneumoniae, Haemophilus influenzae and Branhamella catarrhalis in middle ear effusion during early phase of acute otitis media. Acta Otolaryngol (Stockh) 1990;109:111-8.
• Karma P. Palva T. Kouvalainen K. Karja J. Makela PH. Prinssi VP. Ruuskanen O. Launiala K. Finnish approach to the treatment of acute otitis media. Report of the Finnish Consensus Conference. Ann Otol Rhinol Laryngol 1987;129:S1-19.
• Kato H. Watanabe N. Bundo J. Mogi G. Lymphocyte migration to the middle ear mucosa. Ann Otol Rhinol Laryngol 1994;103:118-24.
• Kauffman F, Lund E, Eddy BE. Proposal for a change in the nomenclature of Diplococcus pneumoniae and a comparison of the Danish and American type designations. Int Bull Bacteriol Nomeccl Taxon 1960;10:31-40.
• Kauppi M, Saarinen L and Käyhty H. Anti-capsular antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rat. J Infect Dis 1993;167:365-71.
• Kauppi M, Eskola J, Käyhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunisation with Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J 1995;14:286-94.
• Kauppi-Korkeila M. Saarinen L. Eskola J. Käyhty H. Subclass distribution of IgA antibodies in saliva and serum after immunisation with Haemophilus influenzae type b conjugate vaccines. Clin Exp Immunol 1998:111:237-42.
• Kehrl JH. Fauci AS. Activation of human B lymphocytes after immunisation with pneumococcal polysaccharides. J Clin Invest1983;71:1032-40.
• Kett K, Brandzaeg P, Radl J, Haaijman JJ. Different subclass distribution of IgA-producing cells in human lymphoid organs and various secretory tissues. J Immunol 1986;136:3631-5.
• Kilian M, mestecky J, Schrohenloher RE. Pathogenic species of the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin A1 protease. Infect Immun 1979;26:143-9.
• Kilian M. Mestecky J. Russell MW. Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol Rev 1988;52:296-303.
• Kilian M. Reinholdt J. Lomholt H. Poulsen K. Frandsen EV. Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. APMIS1996;104:321-38.
• Kilpi T, Syrjänen R, Herva E, Karjalainen T, Eskola J, Takala A. Pneumococcal serotypes in acute otitis media; a prospective cohort study of 329 children. In: 7th International Symposium on Recent Advances in Otitis Media. Fort Lauderle, Florida. June 1999.
• Klein JO. The epidemiology of pneumococcal disease in infants and children. Rev Inf Dis 1981;3:246-53.
• Klein BS. Dollete FR. Yolken RH. The role of respiratory syncytial virus and other viral pathogens in acute otitis media. J Pediatrics1982;101:16-20.
• Korkeila M, Steenroos B, Kilpi T, Takala A, Käyhty H. Antibodies to pneumococcal capsular polysaccharides in saliva of children. In: First International Symposium on Pneumococci and Pneumococcal Diseases. Helsingor, June 1998.
• Korkeila M, Lehtonen H, Åhman H, Odile L, Eskola J, Käyhty H. Salivary anti-capsular antibodies in children immunised with Streptococcus pneumoniae capsular polysaccharide conjugate vaccine. Vaccine 1999; in press.
• Kornfeld SJ, Plaut AG. Secretory immunity and bacterial IgA proteases. Rev Infect Dis 1981;3:521-34.
• Korsud FR, Brandzaeg P. Quantitative immunohistochemistry of immunoglobulin- and J-chain-producing cells in human parotid and submandibular glands. Immunol 1980;39:155-61.
• Koskela M, Leinonen M, Luotonen J. Serum antibody response to pneumococcal otitis media. Pediatr Infect Dis J 1982;1:245-52.
• Kuper CF, Koornstra PJ, Hameleers DMH, Biewenga J, Split BJ, Duijvestijn AM, van Breda Vriesman BJC, Sminia T. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992;13:219-24.
• Käyhty H. Karanko V. Peltola H. Mäkelä PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunisation: no evidence of immunologic tolerance or memory. Pediatrics 1984;74:857-65.
• Käyhty H. Eskola J. Peltola H. Stout MG. Samuelson JS. Gordon LK. Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid. J Inf Dis1987;155:100-6.
• Käyhty H, Åhman H, Rönnberg PR, Tillikainen R, Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995;172:1273-8.
• Lanzavecchia A. Antigen presentation by B lymphocytes: a critical step in T-B collaboration. Curr Top Microbiol Immunol 1986;130:65-78.
• Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985;314:537-9.
• Lee CJ. Banks SD. Li JP. Virulence, immunity, and vaccine related to Streptococcus pneumoniae. Critical Rev Microbiol 1991;18:89-114.
• Leinonen MK. Detection of pneumococcal capsular polysaccharide antigens by latex agglutination, counterimmunoelectrophoresis, and radioimmunoassay in middle ear exudates in acute otitis media. J Clin Microbiol 1980;11:135-40.
• Leinonen M. Antibody responses against pneumococcal polysaccharide antigens in vaccinated persons. Ann Clin Res 1982;14:267-71.
• Leinonen M, Säkkinen A, Kalliokoski R, Luotonen J, Timonen M, Mäkelä PH. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis 1986;5:39-44.
• Lepow ML. Barkin RM. Berkowitz CD. Brunell PA. James D. Meier K. Ward J. Zahradnik JM. Samuelson J. McVerry PH. et al. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) in infants. J Inf Dis 1987;156:591-6.
• Levine MM. Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet 1998;351:1375-6.
• Lue C, Tarkowski A, Mestecky J. Systemic immunisation with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies. J Immunol. 1988;140:3793-800.
• Lue C, Prince SJ, Fattom A, Schneerson R, Robbins JB and Mestecky J. Antibody-secreting peripheral blood lymphocytes induced by immunisation with a conjugate consisting of Streptococcus pneumoniae type 12 F polysaccharide and diphteria toxoid. Infect Immun 1990;57:2547-54.
• Lue, C., van den Wall Blake, A.W., Prince, SJ., Julian, BA., Tseng, ML., Radl, J., Elson, C.O. and Mestecky, J. Intraperitoneal immunisation of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response. Clin Exp Immunol 1994;96:356-63.
• Lund E, Henichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae. In: Methods in Microbiology. Eds. Bergan T, Norris JR. Academic Press, London, 1978: 241-262.
• Lundgren K, Ingvarsson L. Epidemiology of acute otitis media in children. Scand J Infect Dis 1983;39:19-25.
• Luotonen J. Streptococcus pneumoniae and Haemophilus influenzae in nasal cultures during acute otitis media. Acta Otolaryngol (Stockh) 1982;93:295-9.
• Luotonen J, Herva E, Karma P, Timonen M, Leinonen M, Mäkelä PH. The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods. Scand J Infect Dis 1981;13:177-83.
• MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunisation with specific capsular polysaccharides. J Exp Med 1945;82:445-65.
• Male CJ. Immunoglobulin A1 protease production by Haemophilus influenzae and Streptococcus pneumoniae. Infect Immun 1979:26:254-61.
• Mallett CP. Boylan RJ. Everhart DL. Competent antigen-binding fragments (Fab) from secretory immunoglobulin A using Streptococcus sanguis immunoglobulin A protease. Caries Res 1984;18:201-8.
• Malley R, Stack AM, Ferretti ML, Thompson CM and Saladino RA. Anticapsular polysaccharide antibodies and nasopharyngeal colonization with Streptococcus pneumoniae in infant rat. J Infect Dis 1998;178:878-82.
• Manary MJ. Lehmann D. Michael A. Coakley K. Taime J. Montgomery J. Granoff DM. Antigenuria in healthy Papua New Guinean children with nasal Haemophilus influenzae type b carriage. Ann Tropical Paediatrics 1993;13:385-9.
• Mansa B. Kilian M. Retained antigen-binding activity of Fab alpha fragments of human monoclonal immunoglobulin A1 (IgA1) cleaved by IgA1 protease. Infect Immun 1986;52:171-4.
• McDaniel LS. Yother J. Vijayakumar M. McGarry L. Guild WR. Briles DE. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 1987;165:381-94.
• McDermott MR, Bienenstock J. Evidence for a common mucosal immune system. I. Migration of B immunoblasts into intestinal, respiratory and genital tissues. J Immunol 1979;122:1892-8.
• Mestecky J. Russell MW. IgA subclasses. Monog Allerg 1986;19:277-301.
• Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987;7:265-76.
• Mestecky J, Moldoveanu Z, Michalek SM, Morrow CD, Compans RW, Schafer DP, Russell MW. Current options for vaccine delivery systems by mucosal route. J Control Rel 1997;48:243-257.
• Mitchell TJ. Alexander JE. Morgan PJ. Andrew PW. Molecular analysis of virulence factors of Streptococcus pneumoniae. Soc Appl Bacteriol Symp Ser 1997;26:62S-71S.
• Miller MA. Meschievitz CK. Ballanco GA. Daum RS. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period. Pediatrics 1995;95:522-7.
• Mohle-Boetani JC, Ajello G, Breneman E, Deaver KA, Harvey C, Plikaytis BD, Farley MM, Stephens DS, Wenger JD. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 1993;12:589-93.
• Mond JJ. Lees A. Snapper CM. T cell-independent antigens type 2. Ann Rev Immunol 1995;13:655-92.
• Moshier DE, SubbarroB. Thymus-independent antigens: complexity of B-lymphocyte activation-revealed. Immunol Today 1982;3:217-22.
• Mosier DE. Zaldivar NM. Goldings E. Mond J. Scher I. Paul WE. Formation of antibody in the newborn mouse: study of T-cell-independent antibody response. J Inf Dis 1977;136:S14-9, 1977.
• Munoz JL. Insel RA. In vitro human antibody production to the Haemophilus influenzae type b capsular polysaccharide. J Immunol 1987;139:2026-31.
• Murphy TV, Pasor P, Medley F Osterholm T Granoff DM. Decreased haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 1993;122:517-23.
• Murphy TV. Clements JF. Granoff DM. Excretion of Haemophilus influenzae type b polysaccharide antigen in urine of healthy nasopharyngeal carriers. Pediatric Research 1989;26:491-5.
• Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Inf Dis1992;14:801-7.
• Mäkelä PH, Karma P, Sipilä M, Pukander J, Leinonen M. Possibilities of preventing otitis media by vaccination. Scand J Infect Dis 1983;39:S34-8.
• Mäkelä PH and Karma P. Vaccination trials in otitis media: experiences in Finland since 1977. J Pediatr. Infect Dis1989;8S:79-84.
• Mäkelä PH. Eskola J. Peltola H. Takala AK. Käyhty H. Clinical experience with Haemophilus influenzae type b conjugate vaccines. Pediatrics 1990;85:651-3.
• Mäkelä PH, Eskola J, Käyhty H, Takala A. Vaccines against Haemophilus influenzae type b. In: Molecular and Clinical Aspects of Bacterial vaccine development, ed. Ala'Aldeen CCA and Hormaeche CE. John Wiley & Sons Ltd., 1995:41-91.
• Nadal D. Albini B. Chen CY. Schlapfer E. Bernstein JM. Ogra PL. Distribution and engraftment patterns of human tonsillar mononuclear cells and immunoglobulin-secreting cells in mice with severe combined immunodeficiency: role of the Epstein-Barr virus. Internat Arch Allerg Appl Immunol 1991;95:341-51.
• Neufeld F. Uber die agglutina der Pneumokokken und uber die Theorien der Agglutination. Z Hyg Infekt-Kr 1902;40:54-72.
• Nieminen T, Käyhty H, Kantele A. Circulating antibody secreting cells and humoral antibody response after parenteral immunisation with meningococcal polysaccharide vaccine. Scand J Infect Dis 1996;28:53-58.
• Nohynek H. Eskola J. Kleemola M. Jalonen E. Saikku P. Leinonen M. Bacterial antibody assays in the diagnosis of acute lower respiratory tract infection in children. Pediatr Inf Dis J 1995;14:478-84.
• Ofek I. Sharon N. Lectinophagocytosis: a molecular mechanism of recognition between cell surface sugars and lectins in the phagocytosis of bacteria. Infect Immun 1988;56:539-47.
• Pabst HF, Kreth HW. Ontogeny of the immune response as a basis of childhood disease. J Pediatr 1980;97:519
• Parke JC Jr. Schneerson R. Robbins JB. Schlesselman JJ. Interim report of a controlled field trial of immunisation with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg county, North Carolina (March 1974-March 1976). J Inf Dis 1977;136:S51-6.
• Paton JC, Ferrante A. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin. Infect Immun 1983;41:1212-6.
• Paton JC, Rowan-Kelly B, Ferrante A. Activation of human complement by the pneumococcal toxin pneumolysin. Infect Immun 1984;43:1085-7.
• Peltola H, Käyhty H, Sivonen A. Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field trial of 100 000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977;60:730-7.
• Pedersen FK. Henrichsen J. Pneumococcal meningitis and bacteraemia in Danish children 1969-1978. Serotypes, incidence and outcome. AMPIS - Section B, Microbiology 1983;91:129-34.
• Persson CG. Erjefalt JS. Greiff L. Erjefalt I. Korsgren M. Linden M. Sundler F. Andersson M. Svensson C. Contribution of plasma-derived molecules to mucosal immune defence, disease and repair in the airways. Scand J Immunol 1998;47:302-13.
• Pichichero ME, Hall CB, Insel RA. A mucosal antibody response following systemic Haemophilus influenzae type b infection in children. J Clin Invest 1981;67:1482-9.
• Pichichero M, Insel R. Mucosal antibody response to parenteral vaccination with Haemophilus influenzae type b capsule. J Allergy Clin Immunol 1983;72:481-6.
• Pichichero M, Insel R. Relationship with naturally occurring human mucosal and serum antibody to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1982;146:243-8.
• Powers DC, Anderson EL, Lottenbach K and Mink CM. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996;173:1014-8.
• Prellner K, Kalm O, Pedersen FK. Pneumococcal antibodies and complement during and after periods of recurring otitis. Int J Pediatr Otorhinolaryngol 1984;7:39-49.
• Pukander J, Luotonen J, Sipilä M, Timonen M, Karma P. Incidence of acute otitis media. Acta Otolaryngol (Stockh) 1982;93:447-53.
• Quataert SA, Kirch CS, Wiedl LJ, Phipps DC, Strohmeyer S, Cimino CO, Skuse J, Madore DV. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, Lot 89-S. Clin Diagn Lab Immunol 1995;2:590-7.
• Rijkers GT, Mosier DE. Pneumococcal polysaccharides induce antibody formation by human B lymphocytes in vitro. J Immunol 1985;135:1-4.
• Riley ID, Alpers M, Gratten H, Lehmann D, Marshall TFCD, Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 1986;2:877-81.
• Robbins JB, Schneerson R and Szu SC. Perspective hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98.
• Robbins JB, Schneerson R, Andersson P, Smith DH. The Albert Lasker medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. JAMA 1996;276:1181-5.
R2">
• Robbins JB. Myerowitz L. Whisnant JK. Argaman M. Schneerson R. Handzel ZT. Gotschlich EC. Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun 1972;6:651-6.
• Robbins JB. Schneerson R. Glode MP. Vann W. Schiffer MS. Liu TY. Parke JC Jr. Huntley C. Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria. J Allerg Clin Immunol 1975;56:141-51.
• Rosenow C. Ryan P. Weiser JN. Johnson S. Fontan P. Ortqvist A. Masure HR. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 1997;25:819-29.
• Rubins JB. Duane PG. Clawson D. Charboneau D. Young J. Niewoehner DE. Toxicity of pneumolysin to pulmonary alveolar epithelial cells. Infect Immun 1993;61:1352-8.
• Russell H. Tharpe JA. Wells DE. White EH. Johnson JE. Monoclonal antibody recognizing a species-specific protein from Streptococcus pneumoniae. J Clin Microbiol 1990;28:2191-5.
• Russell MW. Lue C. van den Wall Bake AW. Moldoveanu Z. Mestecky J. Molecular heterogeneity of human IgA antibodies during an immune response. Clin Exp Immunol 1992:87:1-6.
• Ruuskanen O, Arola M, Putto-Laurila A, Mertsola J, Meurman O, Viljanen MK, Halonen P. Acute otitis media and respiratory virus infections. Pediatr Infect Dis J 1989;8:94-9.
• Ryan AF, Sharp PA, Harris JP. Lymphocyte circulation to the middle ear. Acta Otolaryngol 1990;109:278-87.
• Sampson JS. Furlow Z. Whitney AM. Williams D. Facklam R. Carlone GM. Limited diversity of Streptococcus pneumoniae psaA among pneumococcal vaccine serotypes. Infect Immun 1997;65:1967-71.
• Santosham M. Wolff M. Reid R. Hohenboken M. Bateman M. Goepp J. Cortese M. Sack D. Hill J. Newcomer W et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991;324:1767-72.
• Sarkkinen H. Ruuskanen O. Meurman O. Puhakka H. Virolainen E. Eskola J. Identification of respiratory virus antigens in middle ear fluids of children with acute otitis media. J Infect Dis1985;151:444-8.
• Sarnesto A. Ranta S. Väänänen P. Mäkelä O. Proportions of Ig classes and subclasses in rubella antibodies. Scand J Immunol 1985;21:275-82.
• Schneerson R. Barrera O. Sutton A. Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980;152:361-76.
• Schneerson R. Robbins JE. Chu CY. Sutton A. Schiffman G. Vann WF. Semi-synthetic vaccines composed of capsular polysaccharides of pathogenic bacteria covalently bound to proteins for the prevention of invasive diseases. Prog Allerg 1983;33:144-58.
• Schneerson R. Robbins JB. Barrera O. Sutton A. Habig WB. Hardegree MC. Chaimovich J. Haemophilus influenzae type B polysaccharide-protein conjugates: model for a new generation of capsular polysaccharide vaccines. Prog Clin Biol Res 1980; 47:77-94.
• Schurin PA, Rehmus JM, Johnson CE, Marchant CD, Carlin SA, Super DM, Van Hare GF, Jones PK, Amrosino DM, Siber GR. Bacterial polysaccharide immunoglobulin for prophylaxis of acute otitis media in high risk children. J Pediatr 1993;123:801-10.
• Sedgwick JD, Holt PG. A solid-phase immunoenzymatic technique for the enumeration of specific antibody secreting cells. J Immunol Met 1983;57:301-9.
• Seong SY, Cho NH, Kwon IC, Jeong SY. Protective immunity to microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect Immun 1999;67:3587-92.
• Seppälä IJ. Rautonen N. Sarnesto A. Mattila PA. Mäkelä O. The percentages of six immunoglobulin isotypes in human antibodies to tetanus toxoid: standardization of isotype-specific second antibodies in solid-phase assay. Eur J Immunol 1984;14:868-75.
• Seppälä I, Mäkelä O. Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling. J Immunol 1989;143:1259-64.
• Shapiro ED. Berg AT. Austrian R. Schroeder D. Parcells V. Margolis A. Adair RK. Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
• Siber GR. Schur PH. Aisenberg AC. Weitzman SA. Schiffman G. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 1980;303:178-82.
• Sims RV. Steinmann WC. McConville JH. King LR. Zwick WC. Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Int Med 1988;108:653-7.
• Sipilä M, Pukander J.Karma P. Incidence of acute otitis media up to the age of 1 ½ years in urban infants. Acta Otolaryngol (Stockh) 1987;104:138-45.
• Skov Sorensen UB. Henrichsen J. C-polysaccharide in a pneumococcal vaccine. Acta Path Microbiol Immunol Scand Sect. C. 1984;92:351-6.
• Skov Sorensen UB. Blom J. Birch-Andersen A. Henrichsen J. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci. Infect Immun 1988;56:1890-6.
• Sloyer JL Jr, Howie VM, Ploussard JH, Amman AJ, Austrian R, Johnston RB Jr. Immune response to acute otitis media in children. Infect Immun 1974;9:1028-32.
• Sloyer JL Jr, Howie WM, Ploussard JH, Schiffman G and Jonston RB Jr.Immune response to acute otitis media. Association between middle ear fluid antibody and the cleaning of clinical infection. J Clin Microbiol 1976;4:306-8.
• Soininen A, Seppälä I, Nieminen T, Eskola J, Käyhty H. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 1999;17:1889-97.
• Spinola SM. Sheaffer CI. Philbrick KB. Gilligan PH. Antigenuria after Haemophilus influenzae type b polysaccharide immunisation: a prospective study. J Pediatrics 1986;109:835-8.
• Sorensen RU. Leiva LE. Giangrosso PA. Butler B. Javier FC 3rd. Sacerdote DM. Bradford N. Moore C. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Inf Dis J 1998;17:685-91.
• Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Inf Dis 1992;165:S49-52.
• Strober W. Harriman GR. Kunimoto DR. Early steps of IgA B cell differentiation. Immunol Res 1991;10:386-8.
• Svennerholm AM. Hanson LA. Holmgren J. Lindblad BS. Nilsson B. Quereshi F. Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women. Infect Immun 1980;30:427-30.
• Sörensen CH. Secretory immunoglobulin in the nasopharynx: implications in otitis media.In: Bernstein J, Ogra P, eds. Immunology of the ear. New York: Raven Press, 1987:259-78.
• Takala AK, Eskola J, Leinonen M, Käyhty H, Nissinen A, Pekkanen E, Mäkelä PH. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunised with an Hib conjugate vaccine. J Infect Dis 1991;164:982-6.
• Takala AK, Santosham S, Almeido-Hill BS, Wolff M, Newcomer W, Reid, Käyhty H, Esko E, Mäkelä PH. Vaccination with Haemophilus influenzae-type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 1993;12:593-9.
• Tarkowski A., Lue C, Moldoveanu Z, Kiyono H, McGhee J and Mestecky J. Immunisation of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA₂-subclass antibody responses. J Immunol 1990;144:3770-8.
• Tarkowski A. Lue C. Moldoveanu Z. Kiyono H. McGhee JR. Prchal JT. Halpern NB. Mestecky J. Systemic immunisation for the induction of IgA responses. Curr Top in Microbiol Immunol 1989;146:161-8.
• Teele DW. Klein JO. Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Inf Dis1989;160:83-94.
• Timens W. Boes A. Rozeboom-Uiterwijk T. Poppema S. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 1989;143:3200-6.
• Tomasz A. Surface components of Streptococcus pneumoniae. Rev Infect Dis 1981;3:190-211.
• Trollfors B. Burman L. Dannetun E. Llompart J. Norrby R. Serotyping of Streptococcus pneumoniae strains by coagglutination and counterimmunoelectrophoresis. J Clin Microbiol 1983;18:978-80.
• Trollmo C, Sollerman C, Carlsten H, and Tarkowsky A. The gut as an inductive site for synovial and extra articular immune responses in rheumatoid arthritis. Ann Rheum Dis 1994;53:377-81.
• Tuomanen E, Liu H, Hengstler B, Zak O, Tomasz A. The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis 1985;151:859-68.
• Tuomanen E, Rich R, and Zak O, Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Resp Dis 1987;135:869-74.
• Tuomanen EI. The biology of pneumococcal infection. Ped Res 1997;42:253-8.
• VanCott JL. Kobayashi T. Yamamoto M. Pillai S. McGhee JR. Kiyono H. Induction of pneumococcalpolysaccharide-specific mucosal immune responses by oral immunisation. Vaccine 1996;14:392-8.
• van de Wijgert JHHM, Verheul AFM, Snippe H, Check IJ, Hunter RL. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution. Infect Immun 1991;59:2750-7.
• Van den Dobbelsteen GP. Brunekreef K. Sminia T. van Rees EP. Effect of mucosal and systemic immunisation with pneumococcal polysaccharide type 3, 4 and 14 in the rat. Scand J Immunol 1992;36:661-9.
• Van den Dobbelsteen GP. Brunekreef K. Sminia T. van Rees EP. Mucosal and systemic immunisation with pneumococcal polysaccharide type 3, 4 and 14 in the rat. Adv Exp Med Biol 1995;371B:1605-10.
• Verheul AFM, Versteeg AA, Reuver MJ, Jansze M, Snippe H. Modulation of the immune response to Pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant quil A depends on the properties of the conjugates. Infect Immun 1989;57:1078-83.
• Virolainen A, Salo P, Jero J, Karma P, Eskola J, Leinonen M. Comparison of PCR assay with bacterial culture for detecting Streptococcus pneumoniae in middle ear fluid of children with acute otitis media. J Clin Microbiol 1994;32:2667-70.
• Virolainen A, Jero J, Käyhty H, Karma P, Leinonen M, Eskola J. Nasopharyngeal antibodies to pneumococcal capsular polysaccharides in children with acute otitis media. J Infect Dis 1995;172:1115-8.
• Virolainen A, Jero J, Käyhty H, Karma P, Leinonen M, Eskola J. Antibodies to pneumococcal pneumolysin and capsular polysaccharides in middle ear fluids of children with acute otitis media. Acta Otolaryngol 1995;115:796-803.
• Virolainen A, Jero J, Chattopadhyay P, Karma P, Eskola J, Leinonen M. Serum antibody responses to pneumolysin compared with responses to pneumococcal capsular polysaccharides in children with acute otitis media. Pediatr Infect Dis J 1996;15:128-33.
• Walker JA, Allen RL, Falmagne P, Johnson MK, Boulnois GJ. Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae. Infect Immun 1987;55:1184-9.
• Wara DW. Host defence against Streptococcus pneumoniae: The role of the spleen. Rev Infect Dis 1981;3:299-309.
• Ward J. Brenneman G. Letson GW. Heyward WL. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med 1990;323:1393-401.
• Watanabe N, Kato H, Mogi G. Induction of antigen spesific IgA-forming cells in the middle ear mucosa. Arch Otolaryngol Head Neck Surg 1988;114:758-62.
• Watson DA. Musher DM. Verhoef J. Pneumococcal virulence factors and host immune responses to them. Eur J Clin Microbiol Infect Dis 1995;14:479-90.
• Weinstein PD. Cebra JJ. The preference for switching to IgA expression by Peyer's patch germinal center B cells is likely due to the intrinsic influence of their microenvironment. J Immunol 1991;147:4126-35.
• Wikström MB, Dahlen G, Kaijser B, Nygren H. Degradation of human immunoglobulins by protease from Streptococcus pneumoniae obtained from various human sources. Infect Immun 1984;44:33-7.
• Willard CY, Hansen AE. Bacterial flora of the nasopharynx in children. Amer J Dis Child 1957;97:318-23.
• Winkelstein JA, Tomasz A. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol 1978;120:174-8.
• Wood WB, Smith MR.The inhibition of surface phagosytosis by the capsular slime layer of pneumococcus type III. J Exp Med 1949;90:85-99.
• Åhman H, Käyhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996;15:134-9.
• Åhman H, Käyhty H, Lehtonen H, Leroy O, Froeschle J and Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;17:211-6.
• Åhman H, Käyhty H, Vuorela A, Leroy O, Eskola J. Dose-dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 1999;17:2726-32.